GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $814,305. The enterprise value is -$4.09 million.
Important Dates
The next estimated earnings date is Friday, May 23, 2025, before market open.
Earnings Date | May 23, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 525,358 shares outstanding.
Current Share Class | 525,358 |
Shares Outstanding | 525,358 |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +164.06% |
Owned by Insiders (%) | 0.09% |
Owned by Institutions (%) | 2.48% |
Float | 524,755 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.20 |
P/TBV Ratio | 0.20 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.03.
Current Ratio | 3.43 |
Quick Ratio | 3.07 |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -382.52% and return on invested capital (ROIC) is -232.68%.
Return on Equity (ROE) | -382.52% |
Return on Assets (ROA) | -118.39% |
Return on Invested Capital (ROIC) | -232.68% |
Return on Capital Employed (ROCE) | -200.71% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.53M |
Employee Count | 4 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.29% in the last 52 weeks. The beta is -2.22, so GRI Bio's price volatility has been lower than the market average.
Beta (5Y) | -2.22 |
52-Week Price Change | -98.29% |
50-Day Moving Average | 3.62 |
200-Day Moving Average | 9.05 |
Relative Strength Index (RSI) | 33.91 |
Average Volume (20 Days) | 326,672 |
Short Selling Information
The latest short interest is 104,998, so 19.99% of the outstanding shares have been sold short.
Short Interest | 104,998 |
Short Previous Month | 251,565 |
Short % of Shares Out | 19.99% |
Short % of Float | 20.01% |
Short Ratio (days to cover) | 0.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -8.24M |
Pretax Income | -12.77M |
Net Income | -10.12M |
EBITDA | -8.23M |
EBIT | -8.24M |
Earnings Per Share (EPS) | -$55.21 |
Full Income Statement Balance Sheet
The company has $5.03 million in cash and $119,000 in debt, giving a net cash position of $4.91 million or $9.34 per share.
Cash & Cash Equivalents | 5.03M |
Total Debt | 119,000 |
Net Cash | 4.91M |
Net Cash Per Share | $9.34 |
Equity (Book Value) | 4.03M |
Book Value Per Share | 7.67 |
Working Capital | 3.98M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -8.61M |
Capital Expenditures | n/a |
Free Cash Flow | -8.61M |
FCF Per Share | -$16.39 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -1,242.53% |
FCF Yield | -1,057.47% |
Analyst Forecast
The average price target for GRI Bio is $115.50, which is 7,351.61% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $115.50 |
Price Target Difference | 7,351.61% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -44.28% |
Stock Forecasts Stock Splits
The last stock split was on February 24, 2025. It was a reverse split with a ratio of 0.0588235:1.
Last Split Date | Feb 24, 2025 |
Split Type | Reverse |
Split Ratio | 0.0588235:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |